A new federal inflation report shows prescription-drug prices fell 3.1% over the past year. But that does not mean every family will see a 3.1% drop at the pharmacy counter.
Prescription drug prices in the United States just recorded a decline not seen in more than six decades.
According to the latest U.S. Bureau of Labor Statistics Consumer Price Index report, prescription-drug prices fell 3.1% over the 12 months ending in July 2026. The decline was also 0.8% in July alone.
The 12-month drop is the smallest annual change in the prescription-drug index since March 1963, when the index fell 3.2%. In other words, July’s decline represents the sharpest year-over-year drop in prescription-drug prices in more than 60 years.
For Latino families, however, the most important question is not simply whether prescription prices are falling.
It is: Will you actually pay less for your medicine?
The answer depends on your insurance, Medicare coverage, the drug you take, whether a generic is available and how your prescription is priced at the pharmacy.
The new numbers stand out because prescription drugs are getting cheaper while many other household and healthcare expenses continue to rise.
Overall consumer prices increased 3.4% over the year ending in July. Food prices rose 3.0%, shelter rose 3.2% and energy prices increased 14.7%.
Healthcare also did not become cheaper across the board.
The BLS reported that the overall medical-care index increased 1.7% over the past year. Medical-care services rose 2.7%, hospital services increased 5.2%, dental services rose 5.1% and home health care increased 9.7%.
Prescription drugs were the exception.
The BLS reported a 3.1% decline in prescription drugs and a 2.7% decline for medicinal drugs overall.
That distinction matters.
A family could therefore experience a lower price for a particular medication while still facing higher costs for a doctor visit, hospital care, dental treatment or other healthcare services.
There is no single explanation in the BLS data as to why prescription prices are falling.
Several forces are operating at the same time, including Medicare’s new negotiated prices, increased generic competition and discounts on certain brand-name medications.
Medicare negotiations are now taking effect
One of the biggest changes is Medicare’s drug-price negotiation program.
The first negotiated prices for 10 Medicare Part D drugs took effect on January 1, 2026. The medications include widely used treatments for conditions such as diabetes, heart disease, blood clots, arthritis, psoriasis and cancer.
CMS’s list of the first 10 negotiated Medicare drugs and prices provides the details for each medication.
The Centers for Medicare & Medicaid Services estimated that the first round of negotiated prices would have saved Medicare about $6 billion if those prices had been in effect in 2023. CMS also estimated that Medicare beneficiaries would save about $1.5 billion in 2026.
That timing is important because the negotiated prices began during the same year that prescription-drug prices began showing an unusually large decline.
But it would be too early to say Medicare negotiations alone caused the entire 3.1% drop.
Economists and drug-pricing experts have pointed to several overlapping forces.
Generic drugs are another important piece of the story
Generic competition can produce large price reductions when a brand-name drug loses patent protection and cheaper alternatives become available.
The BLS prescription-drug index is designed to capture the prices consumers actually pay for prescriptions, including payments involving insurance and Medicare Part D. That means changes in the mix of medications consumers receive can affect the index.
Recent reporting has also pointed to a wave of major drugs losing exclusivity as a potential contributor to lower prescription prices.
For consumers, the practical lesson is straightforward:
A lower prescription price does not necessarily mean the manufacturer simply cut its list price.
The price reflected in the consumer-price data can also change because of insurance negotiations, Medicare payments, pharmacy pricing, discounts or consumers switching from a brand-name drug to a less expensive generic.
The Trump administration is also taking credit for the decline.
The administration launched TrumpRx.gov in February as a direct-to-consumer platform offering discounts on selected prescription medications. The White House says the platform was created through voluntary pricing agreements with pharmaceutical manufacturers and provides discounted cash prices on dozens of brand-name drugs.
The administration has highlighted particularly large discounts for some GLP-1 medications and other high-cost drugs.
Those discounts could help some patients.
But there is an important distinction between a new pricing program existing at the same time as the BLS decline and proving that the program caused the national decline.
The BLS report does not attribute the 3.1% reduction to TrumpRx.
That is why Parriva’s reading of the data is more cautious: TrumpRx is part of a rapidly changing drug-pricing environment, but the federal inflation data do not establish how much of the decline came from TrumpRx.
What does the decline mean for Latino families?
This is where the national number becomes a consumer story.
A lower national prescription-drug index does not guarantee that a particular family will pay less.
The actual amount a patient pays can depend on whether the person has:
- Medicare;
- employer-sponsored insurance;
- an Affordable Care Act marketplace plan;
- Medicaid;
- no insurance;
- a high-deductible plan;
- a generic alternative;
- a drug covered by their plan’s formulary; or
- access to a manufacturer or other discount program.
That matters for Latino communities because insurance coverage and affordability are not evenly distributed across racial and ethnic groups.
KFF reported in March that 59% of U.S. adults were worried about being able to afford prescription drugs for themselves or their families. KFF also found that larger shares of Hispanic adults reported cost-related behaviors such as not filling prescriptions, switching to over-the-counter medicine or skipping doses.
That makes the new BLS data potentially significant — but it also shows why consumers should not assume that a national price decline automatically translates into savings at their own pharmacy.
If you have Medicare, the changes may matter more
For Latino seniors and other Medicare beneficiaries, the 2026 changes deserve particular attention.
Medicare Part D helps pay for covered brand-name and generic prescription drugs.
The first group of negotiated drugs is already subject to Medicare’s new Maximum Fair Prices, while additional negotiated drugs will take effect in future years. CMS says the program will continue expanding over time.
That means the effect of negotiated pricing is not limited to one month of lower prices.
The program is designed to create a growing list of medications with negotiated prices in future years.
Latino Medicare beneficiaries who take one of the selected medications should check their plan information and actual pharmacy costs rather than assuming the national CPI number tells them what they personally will pay.
Medicare.gov’s official prescription-drug information is a useful starting point for understanding Part D coverage.
A lower CPI number does not mean your prescription will be 3.1% cheaper
This may be the most important point in the entire report.
The BLS Consumer Price Index measures average changes in prices, not the amount an individual household will pay.
The agency collects prices from thousands of retail establishments and healthcare providers across the country and combines those observations into national indexes.
So if the prescription-drug index falls 3.1%, that does not mean a medication that cost $100 last year will necessarily cost $96.90 today.
Your cost could fall more.
It could fall less.
It could stay the same.
And in some cases, your out-of-pocket cost could even increase because of changes to your insurance plan, deductible, formulary or coverage.
That is why consumers should compare their actual pharmacy price rather than relying on the national inflation number.
What Latino families can do now
If you regularly take prescription medication, the new data are a reason to check your costs — not a reason to assume they have already fallen.
Ask your pharmacist whether a lower-cost generic is available.
If you have insurance, ask whether the medication’s price has changed under your plan and whether a different pharmacy would charge less.
If you have Medicare Part D, check whether your medication is among those affected by Medicare’s negotiated prices and review your plan’s current drug coverage.
If you are paying cash, compare the cash price with your insurance price. A discount program may sometimes offer a lower price than your insurance copay, although consumers should understand whether a cash purchase counts toward their insurance deductible or out-of-pocket spending.
And never stop or change a prescription solely because you see that drug prices have fallen nationally. Talk with your doctor or pharmacist before changing how you take a medication.
For more Parriva reporting on health policy and issues affecting Latino communities, visit our Health coverage.
The July CPI report offers something unusual in the current inflation landscape: one major category of household healthcare spending is moving sharply downward.
Prescription drugs fell 3.1% over the year, while medical-care services rose 2.7%. Hospital services increased 5.2%, and dental services rose 5.1%.
For families who depend on prescription medication, that decline could eventually translate into meaningful savings.
But the savings will not be distributed equally, and the national CPI does not tell us exactly who benefits.
For Latino families, the most useful takeaway is therefore not simply that prescription prices are at a 60-year low.
It is this:
A historic decline in prescription-drug prices is underway, but whether your family actually saves money depends on the medication you take, your insurance or Medicare coverage, and the price you are offered at the pharmacy.
